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Purpose: The purpose of the study is to understand what clinicians believe defines fluid bolus therapy (FBT) and
the expected response to such intervention.
Methods:We asked intensive care specialists in 30 countries to participate in an electronic questionnaire of their
practice, definition, and expectations of FBT.
Results:We obtained 3138 responses. Despite much variation, more than 80% of respondents felt that more than
250 mL of either colloid or crystalloid fluid given over less than 30 minutes defined FBT, with crystalloids most
acceptable. The most acceptable crystalloid and colloid for use as FBT were 0.9% saline and 4% albumin solution,
respectively. Most respondents believed that one or more of the following physiological changes indicates a re-
sponse to FBT: a mean arterial pressure increase greater than 10 mm Hg, a heart rate decrease greater than 10
beats per minute, an increase in urinary output bymore than 10mL/h, an increase in central venous oxygen sat-
uration greater than 4%, or a lactate decrease greater than 1 mmol/L.
Conclusions: Despite wide variability between individuals and countries, clear majority views emerged to de-
scribe practice, define FBT, and identify a response to it. Further investigation is now required to describe actual
FBT practice and to identify themagnitude and duration of the physiological response to FBT and its relationship
to patient-centered outcomes.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Fluid bolus therapy (FBT) is one of the most common interventions
in intensive care. However, uncertainty exists regarding the strength
of the evidence associating FBT with an independent improvement in
patient centered outcomes and doubt about the magnitude and dura-
tion of its physiological effects [1–4].
Recently, 3 large, multicenter, randomized controlled trials of the
management of severe sepsis demonstrated significant differences in
the volume of fluid administered over the first 6 hours of the manage-
ment of sepsis in critically ill patients [5–7]. In addition, other studies
have demonstrated little consistency in regional definitions of FBT
[8,9]. Furthermore, definitions and clinicians' expectations of the physi-
ological effects of FBT have been shown to vary significantly within a
single country [10], whereas the use of hydroxyethyl starch solutions
(HES) has become controversial due to reported evidence of harm
[11]. However, at an international level, there is little information on
self-reported FBT practice, on what defines an FBT, and on the expected
physiological effects that would confirm a response to FBT for clinicians.
Moreover, substantial difference between stated and recorded practice
would indicate a significant degree of cognitive dissonance among
intensivists providing this essential medical therapy.
Accordingly, we conducted an international survey of intensive care
specialists. Our objectives were to determine their current self-reported
practice, their views of what defined FBT, and their assessment of what
would constitute a response to FBT.2. Methods
2.1. Ethics approval
This study was approved by both our local hospital (HREC no. LNR/
14/Austin/197) and the Monash University Research Ethics Committee
(project no. CF14/2539-2014001354). Completion of the survey ques-
tionnaire was deemed to imply consent.2.2. Survey design and pilot phase
Weused an established electronic survey delivered via a commercial
Web-based survey instrument (www.SurveyMonkey.net, Palo
Alto, CA). We designed a simple questionnaire that could be answered
in less than10minuteswhile still providing comprehensive information
about the volume, the rate of administration, and the types of
fluids used for FBT as well as the expected physiological changes
that would define a response to such therapy. This survey was
originally piloted in an Australian metropolitan, tertiary referral
university hospital and revised before being distributed to Australian
and New Zealand intensivists and emergency physicians in a wider
pilot project which has since been published [10]. No changes were
made as a result of this second pilot phase. The survey is included











Argentina 123 (4%) 41.5 3
Australia 149 (5%) 23.1 6
Austria 107 (3%) 8.5 13
Belgium 108 (3%) 11.2 10
Brazil 178 (6%) 200.4 1
Canada 106 (3%) 35.2 3
Chile 44 (1%) 17.6 2.5
China 302 (10%) 1357 0.2
Colombia 41 (1%) 48.3 1
Denmark 95 (3%) 5.6 17
England, Wales,
and Northern Ireland
67 (2%) 58.4 1
Finland 51 (2%) 5.4 9
France 37 (1%) 65.9 0.5
Germany 178 (6%) 80.7 2
India 182 (6%) 1252 0.2
Italy 203 (6%) 60.2 3
Japan 120 (4%) 127.3 1
Malaysia 27 (1%) 29.7 1
New Zealand 26 (1%) 4.4 6
Saudi Arabia 25 (1%) 28.8 1
Scotland 81 (2.5%) 5.3 15
Singapore 58 (2%) 5.4 11
South Africa 112 (3.5%) 53.2 2
Spain 193 (6%) 46.6 4
Sweden 91 (3%) 9.6 9.5
Switzerland 104 (3%) 8.1 13
The Czech Republic 58 (2%) 10.5 5.5
The Netherlands 25 (1%) 16.8 1.5
The Republic of Ireland 41 (1%) 4.6 9
USA 206 (7%) 316.1 0.5
Total 3138 (100%) 3937.4 0.8
Where number (n) and proportion (%) of respondents are displayed with the 2013 national
population data from the World Bank (http://data.worldbank.org/indicator/SP.POP.TOTL).
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The questionnaire comprised 2 sections, excluding nonidentifying
demographic data. The first section of the survey asked respondents to
identify (a) appropriate fluids for FBT, excludingwhole blood or packed
red cells; (b) the minimum volume of that fluid that constituted a fluid
bolus; and (c) the maximum amount of time for they would allow for
that volume of that fluid to be delivered over while still constituting
FBT. The second section contained 6 items; each itemasked respondents
to identify theminimum change in a specific physiological variable that
they believe constituted a response to FBT,when fluid had been given as
a response to a deficit in that variable. These questionswere designed to
make it clear to the respondent that they were to be answered as if the
decision to give the bolus had already been made. We deliberately did
not assign temporal scales to these expected responses to FBT to isolate
the magnitude of changes that clinicians expect from FBT.
2.4. Survey dissemination
An academic intensivist in each participating country was
approached directly by the authors to act as a national coordinator.
These coordinators invited intensive care specialists in their country to
participate in the survey in a variety of ways, including personal and in-
stitutional contacts, national societies, and through direct approach at
national meetings. Participation was voluntary and anonymous. When
directly approached, specialists completed the questionnaire using a
tablet computer. Where e-mail was used, an invitation was sent by e-
mail containing a hyperlink to the questionnaire. Reminder e-mails
were sent subsequently to encourage participation.
2.5. Population data and missing data
Information regarding the population size of each country in 2013
was obtained from publically available data published by the World
Bank (http://data.worldbank.org/indicator/SP.POP.TOTL). We included
all responses indicating country of origin; those not providing this infor-
mation were excluded from analysis. Responses were analyzed using
the number of respondents completing each individual section of the
questionnaire as a denominator. We did not impute missing data; a
summary of missing data is presented in the ESM (Table E1).
2.6. Statistical methods
Responses were downloaded from theWeb-based survey provider into
an MS Excel (Microsoft, Seattle, WA) spreadsheet for storage and graphics
creation. Statistical analyses were performed using STATA version 13
(Stata Corp, College Station, TX). Results are presented as the overall propor-
tion of all respondents, with the highest and lowest national rates provided
to indicate the range of national responses obtained. The number of respon-
dents who believed a specific fluid was acceptable for use as FBT is used as
the denominator when calculating the responses regarding the minimum
volumeandmaximumdurationof administrationbelieved to constitute FBT.
3. Results
3.1. National rates of response
Overall, 3138 responses were returned from 30 countries on 6 con-
tinents with a combined population of more than 3.9 billion people be-
tween August 1 and December 31, 2014. The overall survey response
rate was 0.8 responses per million/population, with the lowest national
response rate being0.2 permillion (China and India), and the highest 17
(Denmark) (Table 1; Fig. E1 in the ESM). Specialist qualifications in in-
tensive care medicine were held by 73% (2276/3138) of respondents
(Table E2), and 52% (1538/2991) of respondents had been practicing
as a specialist for less than 10 years (Table E3).3.2. Defining FBT
In total, 83% (2616/3138) of respondents completed the first section
of the questionnaire, with national completion rates varying from 51%
(France) to 96% (New Zealand) (Table E1, ESM).
3.3. Crystalloids as FBT
Overall, 73% of respondents felt 0.9% saline was suitable for use as
FBT. German and Austrian physicians found it least acceptable as FBT
fluid (26%); and Saudi Arabian physicians, themost (100%). Similar pro-
portions of respondents felt lactated and acetated solutions to be suit-
able, with similar variability (Table 2).
For all crystalloid solutions, more than 90% of respondents felt that
more than 250 mL of fluid had to be given to constitute FBT (Table 3).
More than 80% of respondents felt that crystalloid solutions had to be
administered in less than 30 minutes to constitute FBT (Table 4).
3.4. Colloid as FBT
Fewer respondents felt that colloid solutions were suitable for use as
FBT. Four percent albumin was the most widely accepted colloid (46%),
with a range of national responses from 19% (Austria) to 95% (Australia).
With only 27% of respondents believing HES to be suitable for use as FBT,
it was the least acceptable colloid and fluid overall (Table 2).
Approximately 80% of respondents felt that more than 250 mL of
most colloid solutions had to be given to constitute FBT (86% in the
case of 6% HES, 79% for 4% albumin, and 87% for gelatins). Only 19% of
respondents felt that more than 100 mL of 20% albumin had to be
given to constitute FBT (Table 3).
Table 2
Defining the fluids acceptable for use as fluid bolus therapy
Region 4% albumin 20% albumin HES Gelatin 0.9% saline CSL Acetate Total
Argentina 32 (31%) 24 (23%) 30 (29%) 33 (32%) 97 (94%) 51 (50%) 53 (51%) 103
Australia 132 (95%) 46 (33%) 6 (4%) 36 (26%) 124 (89%) 112 (81%) 130 (94%) 139
Austria 17 (19%) 29 (32%) 45 (49%) 41 (45%) 24 (26%) 56 (62%) 53 (58%) 91
Belgium 42 (44%) 38 (40%) 41 (43%) 40 (42%) 62 (65%) 80 (84%) 71 (75%) 95
Brazil 62 (41%) 40 (26%) 31 (21%) 17 (11%) 136 (90%) 89 (59%) 101 (67%) 151
Canada 77 (77%) 45 (45%) 13 (13%) 4 (4%) 84 (84%) 83 (83%) 68 (68%) 100
Chile 9 (22%) 20 (49%) 6 (15%) 8 (20%) 36 (88%) 21 (51%) 21 (51%) 41
China 84 (37%) 96 (42%) 104 (45%) 81 (35%) 186 (81%) 137 (60%) 129 (56%) 230
Colombia 12 (39%) 9 (29%) 8 (26%) 4 (13%) 23 (74%) 19 (61%) 24 (77%) 31
Denmark 51 (61%) 45 (54%) 4 (5%) 1 (1%) 76 (90%) 74 (88%) 47 (56%) 84
England, Wales, and Northern Ireland 31 (58%) 23 (43%) 3 (6%) 18 (34%) 31 (58%) 37 (70%) 52 (98%) 53
Finland 23 (49%) 23 (49%) 1 (2%) 2 (4%) 27 (57%) 47 (100%) 23 (49%) 47
France 7 (37%) 6 (32%) 9 (47%) 11 (58%) 18 (95%) 11 (58%) 14 (74%) 19
Germany 38 (25%) 59 (39%) 49 (32%) 57 (38%) 40 (26%) 124 (82%) 80 (53%) 152
India 35 (21%) 21 (13%) 34 (21%) 35 (21%) 130 (80%) 87 (53%) 86 (53%) 163
Italy 54 (36%) 68 (45%) 84 (55%) 83 (55%) 111 (73%) 112 (74%) 92 (61%) 152
Japan 40 (51%) 12 (15%) 19 (24%) 0 (0%) 38 (48%) 63 (80%) 50 (63%) 79
Malaysia 15 (60%) 4 (16%) 4 (16%) 22 (88%) 19 (76%) 16 (64%) 22 (88%) 25
New Zealand 20 (80%) 7 (28%) 0 (0%) 0 (0%) 23 (92%) 24 (96%) 21 (84%) 25
Saudi Arabia 16 (73%) 10 (45%) 3 (14%) 1 (5%) 22 (100%) 13 (59%) 10 (45%) 22
Scotland 37 (51%) 9 (13%) 4 (6%) 38 (53%) 48 (67%) 56 (78%) 66 (92%) 72
Singapore 47 (87%) 13 (24%) 16 (30%) 22 (41%) 47 (87%) 39 (72%) 49 (91%) 54
South Africa 26 (29%) 19 (21%) 55 (62%) 41 (46%) 45 (51%) 68 (76%) 64 (72%) 89
Spain 31 (20%) 61 (40%) 54 (36%) 91 (60%) 143 (94%) 101 (66%) 95 (63%) 152
Sweden 63 (78%) 50 (62%) 8 (10%) 11 (14%) 39 (48%) 77 (95%) 36 (44%) 81
Switzerland 27 (30%) 30 (33%) 26 (29%) 28 (31%) 58 (64%) 70 (77%) 69 (76%) 91
The Czech Republic 17 (33%) 17 (33%) 25 (49%) 27 (53%) 25 (49%) 51 (100%) 42 (82%) 51
The Netherlands 6 (29%) 10 (48%) 3 (14%) 0 (0%) 16 (76%) 13 (62%) 13 (62%) 21
The Republic of Ireland 17 (53%) 12 (38%) 4 (13%) 13 (41%) 22 (69%) 11 (34%) 30 (94%) 32
USA 124 (73%) 77 (45%) 10 (6%) 4 (2%) 158 (92%) 131 (77%) 118 (69%) 171
Overall proportion 1192 (46%) 923 (35%) 699 (27%) 769 (29%) 1908 (73%) 1873 (72%) 1729 (66%) 2616
Highest national proportion 95% 62% 62% 88% 100% 100% 98% 103
Lowest national proportion 19% 13% 0% 0% 26% 34% 44% 139
Median (IQR) 43% (30%-61%) 36% (27%-45%) 21% (11%-35%) 32% (7%-44%) 76% (60%-90%) 73% (60%-82%) 68% (56%-81%) 36% (27%-45%)
Overall proportion calculated as the total number finding that fluid acceptable/the number of respondents answering this section (2616). 4% albumin indicates 4% human albumin solu-
tion; 20% albumin, 20% albumin solution; gelatin, 4% succinylated gelatin solution; 0.9% saline, 0.9% sodium chloride solution; CSL, compound sodium lactate solution; acetate, acetated
solution, proprietary name Plasmalyte; IQR, interquartile range.
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atins had to be administered in less than 30 minutes to constitute FBT,
but 90% of respondents felt that 20% albumin administered in less
than 1 hour constituted FBT (Table 4).Table 3
Defining fluid bolus therapy by volume
Volume of fluid
Fluid type ≥100 mL N125 mL N250
Colloids
4% albumin
n (%) 151 (13%) 89 (8%) 732 (
Range 0%-64% 0%-26% 18%-8
20% albumin
n (%) 729 (81%) 67 (7%) 98 (1
Range 48%-100% 0%-21% 0%-33
HES
n (%) 55 (8%) 39 (6%) 345 (
Range 0%-50% 0%-25% 0%-10
Gelatin
n (%) 49 (7%) 47 (6%) 426 (
Range 0%-24% 0%-50% 0%-10
Crystalloids
0.9% saline
n (%) 56 (3%) 41 (2%) 675 (
Range 0%-21% 0%-10% 8%-84
Acetate
n (%) 46 (3%) 39 (2.12%) 654 (
Range 0%-19% 0%-11% 0%-78
CSL
n (%) 45 (3%) 35 (2%) 641 (
Range 0%-18% 0%-8% 10%-7
Range is defined by the lowest and highest rates among the individual national responses.3.5. Defining the expected response to FBT
Intotal,76.5%(2400/3138)ofrespondentscompletedthesecondsectionofthe
questionnaire, with national response rates varying from43% to 92.5% (Table 5).mL N500 mL N750 mL N1000 mL
63%) 186 (16%) 2 (0%) 10 (1%)
6% 0%-38% 0%-3% 0%-3%
0.85%) 8 (1%) 0 (0%) 2 (0%)
% 0%-9% 0%-0% 0%-3%
50%) 221 (32%) 10 (2%) 19 (3%)
0% 0%-55% 0%-9% 0%-33%
56%) 198 (26%) 11 (1%) 23 (3%)
0% 0%-100% 0%-5% 0%-100%
36%) 731 (39%) 32 (2%) 333 (18%)
% 7%-71% 0%-5% 0%-40%
35%) 728 (40%) 42 (2%) 334 (18%)
% 11%-80% 0%-6% 0%-67%
38%) 672 (39%) 34 (2%) 276 (16%)
6% 0%-62% 0%-6% 0%-60%
Table 4
Defining fluid bolus therapy by rate of administration
Rate of administration
Fluid type b10 min b30 min b1 h b2 h b4 h b6 h
Colloids
4% albumin
n (%) 362 (31%) 574 (49%) 182 (16%) 28 (2%) 11 (1%) 4 (0%)
Range 9%-67% 31%-75% 0%-39% 0%-19% 0%-19% 0%-4%
20% albumin
n (%) 241 (27%) 437 (49%) 149 (17%) 36 (4%) 25 (3%) 12 (1%)
Range 0%-50% 22%-100% 0%-33% 0%-33% 0%-22% 0%-25%
HES
n (%) 199 (29%) 355 (52%) 105 (15%) 24 (3.5%) 3 (0%) 1 (0%)
Range 0%-100% 0%-100% 0%-37% 0%-21% 0%-33% 0%-2%
Gelatin
n (%) 251 (33%) 369 (49%) 116 (16%) 11 (1%) 3 (0%) 4 (1%)
Range 0%-100% 0%-75% 0%-100% 0%-12% 0%-3% 0%-5%
Crystalloids
Saline
n (%) 644 (35%) 875 (48%) 251 (14%) 54 (3%) 12 (1%) 7 (0%)
Range 14%-76% 19%-86% 0%-29% 0%-7% 0%-4% 0%-2%
Acetate
n (%) 603 (33%) 876 (48%) 264 (14%) 64 (4%) 11 (1%) 9 (1%)
Range 12%-76% 22%-82% 0%-33% 0%-11% 0%-5% 0%-3%
CSL
n (%) 568 (34%) 812 (48%) 223 (13%) 54 (3%) 11 (1%) 11 (1%)
Range 9%-76% 22%-79% 0%-30% 0%-10% 0%-4% 0%-2%
Range is defined by the lowest and highest rates among the individual national responses.
Table 5
Defining what constitutes a physiological response to fluid bolus therapy




What is the minimum change in MAP that you believe constitutes a response to
FBT?
0-5 mm Hg 118 (5%) 0%-22%
5-10 mm Hg 1063 (44%) 24%-67%
10-15 mm Hg 859 (36%) 14%-53%
15-20 mm Hg 248 (10%) 0%-19%
20-25 mm Hg 68 (3%) 0%-10%
N25 mm Hg 44 (2%) 0%-6%
What is the minimum change in HR that you believe constitutes a response to FBT?
0-5 bpm 63 (2.5%) 0%-11%
5-10 bpm 652 (27%) 5%-47%
10-15 bpm 1020 (42.5%) 22%-59%
15-20 bpm 474 (20%) 5%-29%
20-25 bpm 113 (5%) 0%-19%
N25 bpm 78 (3%) 0%-10%
What is the minimum change in central venous pressure that you believe
constitutes a response to FBT?
0-2 mm Hg 408 (17%) 5%-28%
2-4 mm Hg 1258 (53%) 28%-68%
4-6 mm Hg 523 (22%) 11%-41%
6-8 mm Hg 100 (4%) 0%-14%
8-10 mm Hg 77 (3%) 0%-13%
N10 mm Hg 34 (1%) 0%-6%
What is the minimum change in hourly UO that you believe constitutes a response
to FBT?
0-5 mL/h 97 (4%) 0%-14%
5-10 mL/h 370 (15%) 3%-31%
10-15 mL/h 460 (19%) 4%-34%
15-20 mL/h 487 (20%) 4%-46%
20-25 mL/h 423 (18%) 4%-29%
25-30 mL/h 563 (24%) 6%-48%
What is the minimum change in central venous oxygen saturation that you believe
constitutes a response to FBT?
0%-2% 118 (5%) 0%-11%
2%-4% 513 (21%) 4%-39%
4%-6% 998 (42%) 22%-56%
6%-8% 382 (16%) 8%-39%
8%-10% 225 (9%) 3%-18%
N10% 164 (7%) 0%-22%
What is the minimum change in blood lactate concentration that you believe
constitutes a response to FBT?
0-0.5 mmol/L 258 (11%) 0%-19%
0.5-1 mmol/L 915 (38%) 16%-56%
1-1.5 mmol/L 618 (26%) 16%-39%
1.5-2.0 mmol/L 340 (14%) 0%-24%
2.0-2.5 mmol/L 142 (6%) 0%-12%
N2.5 mmol/L 127 (5%) 0%-26%
Clinician beliefs regarding the minimum physiological changes required after FBT to con-
stitute a response. Range between countries is defined by the lowest and highest rates
among the individual national responses.
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than 50% of respondents believed that mean arterial pressure (MAP)
must increase by 10mmHg ormore to indicate a response to FBT. Sim-
ilarly, more than 70% of respondents believed that heart rate (HR)must
fall by 10 beats per minute (bpm) or more to constitute a response to
FBT.More than 80% believed that central venous pressuremust increase
by 2mmHg ormore to constitute a response to FBT. More than 80% be-
lieved that urine output (UO) had to increase by 10 mL/h or more, and
more than 70% believed that central venous oxygen saturationmust im-
prove by 4% or more to constitute a response to FBT. More than 50% of
respondents felt that lactate should fall by more than 1 mmol/L to con-
stitute a response to FBT (Table 5).
4. Discussion
4.1. Statement of key findings
We surveyed an international cohort of more than 3000 intensivists
in 30 countries and identified significant variation in self-reported FBT
practice within and between different countries. However, clear major-
ity trends emerged: crystalloids are preferred over colloids; a volume
greater than 250mL given over less than 30minutes defines an episode
of FBT and, finally, each one ormore of these:MAP increase greater than
10 mm Hg, an HR decrease greater than 10 bpm, an increase in UO
greater than 10 mL/h, and a drop in lactate concentration greater than
1 mmol/L was reported to define a response to FBT.
4.2. Relationship with previous studies
International variability in the documented practice of FBT is
established. However, in the FENICE study, the median volume of fluid
administered was 500 mL over approximately 30 minutes with crystal-
loids used in preference [9]. A study of 2694 episodes of FBT in 777 pa-
tients across 19 French intensive care units (ICUs) suggested that a
median of 3 boluses are given per patient, also with marked variability
in the rate and volume of FBT [8]. The most commonly used fluid was
0.9% saline. In contrast to these European studies, an observational
study in an Australian ICU found that 750mL of, most commonly, 4% al-
bumin solution was given most often for FBT, with FBT contributing to
more than 50% of fluid balance on the first ICU day [12]. A previouscross-sectional survey of patients receiving fluid resuscitation in 391
ICUs in 25 countries in 2007 found that more than 50% of patients re-
ceived FBT on the day of their admission, with more than 30% still re-
ceiving FBT on day 6 [13].
Even among albumin users such as Australian and NewZealand, col-
loid consumption has also been falling compared to crystalloid use [14],
likely due to the reduction in the use of HES, as a consequence of emerg-
ing high-level randomized evidence of harm [11,15–17]. Albumin solu-
tions have been shown to be safe in critically ill patients without
traumatic brain injury [18,19] and may be beneficial in patients with
septic shock [20,21]. Concentrated 20% solutions of albumin may offer
safe and effective small volumeFBT given concerns regardingfluid over-
load and patient outcome [22], although they appear to be infrequently
used [8,9]. However, they can be more than 100 times more expensive
131N.J. Glassford et al. / Journal of Critical Care 35 (2016) 126–132than 0.9% saline in some countries, and it is possible that clinical equi-
poise regarding their safety persists [23,24]. There is no high level evi-
dence for the use of gelatine solutions [25].
Several studies have indicated that hypotension, low UO, and
markers of inadequate tissue perfusion such as low mixed venous oxy-
gen saturations or a rising lactate trigger FBT [8,9,12,13]. Thus, the use of
these features to indicate a response, as seen in our survey, is logical.
However, we found substantial variability both within and between
countries regarding the physiological changes required to constitute a
response to FBT and that stated expectations appear to be divorced
from current evidence. A recent pharmacodynamic assessment of the
cardiovascular effects of FBT demonstrated that the modest effects of
250 mL of crystalloid delivered as 5 50-mL boluses over 5 minutes on
cardiac output peak after 1 minute and dissipate within 10 minutes, re-
gardless of fluid responsiveness [26]. In our study, although most re-
spondents felt that a 10 mm Hg increase in MAP indicated a response
to FBT, in a recent systematic review, the median change reported
post-FBT was 7 mm Hg immediately after and 3 mm Hg at 60 minutes
[4]. Similarly, although most respondents aimed for a greater than
10 bpm decrease in HR after FBT, a median decrease of 2 bpm immedi-
ately post-FBT and 1 bpm at 60 minutes has been reported [4]. The ef-
fects of FBT on UO are poorly described in the literature but range
from a 40mL/h decrease to a 13mL/h increase [4]; most intensivists be-
lieved that UO had to increase by more than 10 mL/h to show a re-
sponse. This separation between the physiological effects of FBT
reported in the literature and the expectations of the respondents was
present across all hemodynamic parameters [4,26].
4.3. Study implications
The findings of this survey demonstrate thatmost intensivists define
FBT as a bolus of more than 250 mL of either colloid or crystalloid fluid
given over less than 30 minutes and a response to FBT as an MAP in-
crease greater than 10 mm Hg, an HR decrease greater than 10 bpm,
and an increase in urinary output bymore than 10mL/h. Such operative
definitions of FBT and response to FBT now allow studies of the epide-
miology of FBT in hospitals and of the response rate to such interven-
tion. This is likely important because 25 to more than 200 million
separate exposures to intravenous fluids could occur in the United
States alone each year [27,28].
In 7 of 30 countries, more than 40% of respondents and 27% of all re-
spondents believed 6% HES solution to be acceptable for use as FBT
(Table 2). This is substantially higher than the 16% reportedly not
avoiding HES use in the international survey component of the system-
atic review [29]. This is despite high-level randomized controlled trials
[15–17] and meta-analyses [11,30] demonstrating harm as well as
widespread concern and regulatory body warning regarding HES use
in critically ill patients.[31].
4.4. Study strengths and limitations
Our study has several strengths. First, this is the largest international
FBT survey of individual intensivists to date,with thebreadthof interna-
tional involvement offering significant external validity. Second, FBT is a
ubiquitous but surprisingly unexplored aspect of critical care manage-
ment. Third, our findings provide insight into the national and interna-
tional variation that exists in FBT practice. Fourth, it is the first to
document both the variation in the physiological response that clini-
cians internationally expect from FBT and the separation that exists be-
tween these and the responses described in the literature. Fifth, we
subjected our survey to a robust assessment pre-release, using expert
review, a piloted trial, and a binational trial published in a peer-
reviewed journal [10] to refine our approach.
This study also has some limitations. First, as a voluntary survey of
self-reported practice, our results do not necessarily represent actual
practice. However, several studies have demonstrated acceptablecorrelations between self-reported and documented practice with
such self-reporting being likely to be useful in representing a spectrum
of clinical behavior [32,33]. Second, given ourmethod of survey dissem-
ination,we cannot impute anappropriate denominator to calculate a re-
sponse rate; however, given the variability of the responses, even if
significant selection bias was present, it is likely that practice interna-
tionally is even more variable than is reported by the respondents.
Third, a varying number of respondents in each country ceased their
progression through the survey at various points. This may reflect the
fact the surveywas only presented in English or the complex and polar-
izing nature of studies examining fluid administration. Documented de-
livery of FBT suggests international variation in practice, and it may be
that our descriptions of the therapy or expected response were incom-
patible with local practice patterns [9,13]. The lack of an associated
timeframe regarding response to FBT may have resulted in confusion;
however, we were seeking an objective, quantitative measure of the
maximal response to FBT. To this end, more subjective clinical markers
of response to FBT, such as skin mottling or capillary refill time, were
omitted. Alternatively, the term response may have been felt to be un-
clear, and some respondents may have felt the terminology could
have encompassed both positive and negative changes in the variable
being investigated. The presentation of responses as discrete incremen-
tal changes may have limited the accuracy of responses. Fourth, we did
not undertake formal reliability testing. However,more than 3000 clini-
cians from 30 countries participated in this study, making it the largest
assessment of individual practice in the critical care literature and pro-
viding the first available global assessment of the characteristics and ex-
pectations of FBT in this setting.
5. Conclusions
In an international survey,we foundmajor interindividual and inter-
country variations in self-reported FBT and the expected physiological
changes that define a response to FBT. However, clear majority views
emerged to define FBT and a response to such therapy. Such definitions
now enable amore systematic study of the epidemiology of FBT use, the
response rate to FBT, the duration of such a response, and the impact on
patient-centered outcomes.
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